[Double-blind comparison of L-keflex and cephalexin (Keflex) in dental infections (author's transl)]

In order to evaluate efficacy and safety of L-Keflex (granule form of sustained release cephalexin), a double blind study comparing it with Keflex (capsule of regular cephalexin) was conducted in dental infections. Evaluable cases in adults for efficacy of the drugs were 196 consisting of 97 for L-Keflex and 99 for Keflex. Those in children were 19 (8 for L-Keflex and 11 for Keflex). There were no significant differences in background of the patients and severity of the diseases between both groups (L-Keflex and Keflex groups). The daily doses used in both groups were 1,000 mg in adults and 500 mg in children, respectively. The dose was given in two divided doses for L-Keflex group and in four divided doses for Keflex group. Following are evaluation by the committee members for the study: Adults 1. Clinical response rate at final therapy day was 93.8% in L-Keflex group and 92.9% in Keflex group, showing no significant difference between both groups. 2. No significant difference in severity of subjective and objective symptoms between both groups was observed at each therapy day. 3. Side effects were found in 6.7% of 105 patients receiving L-Keflex and in 5.6% of 107 patients with Keflex, and there was no significant difference between both groups. As the side effects, gastrointestinal symptoms, rash and itching were observed, but no any other side effects were found in both groups. Children 1. As shown in the above, number of the cases enough to evaluate statistically was not obtained, but all of both groups clinically responded to the drugs. 2. As for side effects diarrhea was observed in only one patient of Keflex group consisting of 12 patients. In the patient, however, discontinuation of the drug was not required and the side effect disappeared during the therapy. From the above results, L-Keflex (granule) is judged to have more convenience than Keflex (capsule) in that (1) it can be administered with b.i.d. regimen and (2) it can be easily taken in dental patients such as patients having difficulty in opening mouth of swallowing pain.

[Clinical evaluation of clindamycin-2-phosphate in infectious diseases (author's transl)]

Clindamycin-2-phosphate (7(S)-chloro-7-deoxylincomycin-2-phosphate) is a new semi-synthetic antibiotic. It is recognized that the drug itself is inactive against bacteria in vitro but it is hydrolyzed rapidly to active clindamycin, drug intramuscular or intravenous administration. Clindamycin-2-phosphate was administrated intravenously to seven patients with infections, except one intramuscularly, 300 approximately 600 mg, every 8 or 12 hours a day, for 2 approximately 12 days. Three patients (1 bacterial pneumonia, 1 chronic bronchitis and 1 urinary tract infection due to E. coli) recovered from their infection; one patient (bacterial infection in bronchiectasis) partially responded; and three patients (1 urinary tract infection due to E. coli, 1 pneumonia due to Mycoplasma pneumoniae and 1 patient with mycoplasmal pneumonia and acute biliary tract infection) failed to respond to the drug. No remarkable side effect was noted except pain at intramuscular injection site in one patient.

[Distribution of catecholamine containing nerve endings in the hypothalamus of the rhesus monkey]

Using the Falck-Hillarp method, the distribution of catecholamine nerve terminals in the rhesus monkey hypothalamus was studied. The distribution pattern was fundamentally similar to that in the rat, cat and human fetus; abundunt catecholamine varicosities (presumed noradrenaline nerve terminals) were observed in the dorsomedial nucleus, supraoptic nucleus, paraventricular nucleus, medial forebrain bundle, periventricular layer and internal layer of the infundibulum, while little were in the mamillary nucleus, ventromedial nucleus and anterior hypothalamic area. A band of diffuse green fluorescence (dopamine nerve terminals) was observed around the capillary loops in the external layer of the infundibulum. the discrepancy with the rat was noted in the abundunt noradrenaline nerve terminals in the suprachiasmatic nucleus and denser innervation of them in the arcuate nucleus and internal layer of the infundibulum. In addition to the noradrenaline nerve fibers from the peripheral sympathetic NA nerve, the noradrenaline nerve terminals of central origin closely approximated to the small intracerebral vessels.

Histochemical mapping of dopamine neurons and fiber pathways in dog mesencephalon

A topographic mapping of dopamine (DA)-containing neurons and fibers was done mainly in the mesencephalon of the dog using the fluorescent histochemical technique of Falck and Hillarp. The extensive DA neuron system was found to be located in the ventral and medial regions of the mesencephalon; the pars compacta of the substantia nigra, the area almost corresponding to the ventral tegmental area of Tsai (which consists of three groups, a caudal, the nucleus parabrachialis pigmentosus, a ventral, the nucleus paranigralis and a rostral, the caudal part of the nucleus tegmentalis ventralis of Tsai), the nucleus linearis of the raphe, and the mesencephalic reticular formation. The nigro-neostriatal projection can be traced in the non-treated or nialamide plus L-dopa treated puppies without the lesion-degeneration technique. Most fibers arising from these DA cell groups assemble at the prerubral area and ascend just dorsal to the medial forebrain bundle. Most fibers turn laterally at the lateral hypothalamus and enter the neostriatum via the dorsal part of the subthalamic nucleus, the zona incerta and the capsula interna. These findings show that the distribution of DA neurons and the nigro-neostriatal pathway are fundamentally similar to those in other mammals. In this study, the processes of the nigral and paranigral DA neurons have been demonstrated to project into the pars reticulata in the dog.